Key result
Prospective randomized trials with well-defined, long-term outcome measures are required to advance the management of unstable coronary artery disease and identify optimal treatment strategies.
Highlights the need for future prospective randomized trials to optimize the use of new therapies in unstable coronary artery disease.
Answers are grounded in this paper and cite their sources.
Existing data insufficient to guide unstable CAD management; leaves open optimal strategies pending prospective RCTs with long-term outcomes.
Unstable coronary artery disease continues to pose a major challenge to clinicians. The advent of new therapies, such as percutaneous transluminal coronary angioplasty, low-molecular-weight heparins, and glycoprotein IIb/IIIa inhibitors, provides new management options for this indication but also raises new questions with regard to optimal management. Prospective randomized trials with well-defined, long-term outcome measures and a means of identifying which patients will derive most benefit from each treatment, together with a means of rapid and clear dissemination of study results and implications, are required in order to advance the management of unstable coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Verheugt et al. (1999) conducted a review in Unstable coronary artery disease. Management strategies (PTCA, LMWH, GP IIb/IIIa inhibitors) was evaluated. Prospective randomized trials with well-defined, long-term outcome measures are required to advance the management of unstable coronary artery disease and identify optimal treatment strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: